FDA Press Announcements · September 21, 2026 · Primary source
FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing
Summary
FDA issued a direct final rule clarifying that non-animal testing methods may be used, where appropriate, to assess the safety of drugs and biological products intended for human use before first-in-human trials. The rule updates FDA's existing regulations and reflects the agency's stated priority of advancing alternatives to animal testing in the drug and biologics development pathway.
What this may mean
Drug and biologics manufacturers may substitute qualifying non-animal methods for certain preclinical safety studies under the updated regulations. The rule does not directly affect healthcare provider operations, billing, or compliance programs, and its primary operational impact falls on pharmaceutical and biotech sponsors of IND applications.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Press Announcements · October 5, 2026FDA Seeks Public Input to Support Ibogaine ResearchScore 58
- FDA Press Announcements · October 24, 2026FDA Issues Final Guidance on Prescription Drug Apps and SoftwareScore 46
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition ProductsScore 40
- FDA Press Announcements · August 28, 2026FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in AdultsScore 40
- FDA Press Announcements · August 28, 2026August 28, 2026 - FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood DisorderScore 33
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Grants Accelerated Approval to a New Breast Cancer TreatmentScore 32